From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC

Paola Bordi,Marzia Del Re,Roberta Minari,Eleonora Rofi,Sebastiano Buti,Giuliana Restante,Anna Squadrilli,Stefania Crucitta,Chiara Casartelli,Letizia Gnetti,Cinzia Azzoni,Lorena Bottarelli,Iacopo Petrini,Agnese Cosenza,Leonarda Ferri,Elena Rapacchi,Romano Danesi,Marcello Tiseo

Lung Cancer（2019）

引用 39|浏览58

暂无评分

摘要

•Plasmatic levels of EGFR activating mutations at baseline affect prognosis.•The plasmatic mutational load inversely correlates with outcome measures.•Therascreen selects patients with high mutational load sample and worst outcome.•T790M loss after progression is associated to EGFR-independent resistance mechanism.

查看译文

关键词

Osimertinib,Liquid biopsy,NSCLC,EGFR mutation,T790M

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要